Influence of factor V HR2 on thrombin generation and clinical manifestation in rare bleeding disorders

Pathophysiology of Haemostasis and Thrombosis

Volumn 34, Issue 6, 2006, Pages 279-283

  Strey, Rüdiger F ^a   Siegemund, Annelie ^b   Siegemund, Thomas ^b   Schubert, Christine ^c   Schuster, Gudrun ^a   Wulff, Karin ^a   Herrmann, Falko H ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c HELIOS KLINIKUM ERFURT   (Germany)

Author keywords

Endogenous thrombin potential; Factor V HR2 haplotype; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; RECOMBINANT THROMBOPLASTIN; THROMBIN;

ARTICLE; BLEEDING DISORDER; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; HAPLOTYPE; HOMOZYGOSITY; HUMAN; PRIORITY JOURNAL; SAMPLE; THROMBIN TIME; THROMBOSIS;

BLOOD COAGULATION DISORDERS; FACTOR V; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HETEROZYGOTE; HOMOZYGOTE; HUMANS; RISK FACTORS; THROMBIN;

EID: 33745076855     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093108     Document Type: Article

References (29)

1. Dahlbäck B, Carlsson M, Svensson P: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-1008.
2. Rosendaal FR, Koster JP, Vandenbroucke JP, Reitsma PH: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85: 1504-1508.
3. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-917.
4. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-1506.
5. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PJ: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
6. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B : Activated protein C resistance caused by Arg506 → Gln mutation in factor Va. Lancet 1994;343:1361-1362.
7. Voorberg J, Roelse J, Koopman R, Büller H, Berends F, ten Cate JW, Mertens K, van Mourik JA: Association of idiopathic venous thromboembolism with single point mutation at Arg506 of factor V. Lancet 1994;343:1535-1536.
8. Zöller B, Dahlbäck B: Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994;343:1536-1538.
9. Castaman G, Faioni EM, Tosetto A, Bernardi F: The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis. Haematologica 2003;88:1182-189.
10. Dargaud Y, Meunier S, Negrier C: Haemophilia and thrombophilia: an unexpected association! Haemophilia 2004;10:319-326.
11. Castoldi E, Brugge JM, Nicolaes DAF, Girelli D, Tans G, Rosing J: Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood 2004;103:4173-4179.
12. Castoldi E, Rosing J, Girelli D, Hoekema L, Lunghi B, Migozzi F, Ferraresi P, Friso S, Corrocher R, Tans G, Bernardi F: Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma. Thromb Haemost 2000;83:362-365.
13. Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, Mannucci PM: A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997;90:1552-1557.
14. Herrmann FH, Salazar-Sanchez L, Jimenez-Arce G, Grimm R, Schroder W: High prevalence of FVHR2 polymorphism in Costa Rican Indians who have no FVL. Thromb Haemost 2001;85:1020-1021.
15. Herrmann FH, Wulff K, Auberger K, Aumann V, Bergmann F, Bratanoff E, Franke D, Grundeis M, Kreuz W, Lenk H, Losonszy H, Maak B, Marx G, Mauz-Körholz C, Pollmann H, Serban M, Sutor A, Syrbe G, Vogel G, Weinstock N, Wenzel E, Wulff K: Molecular biology and clinical manifestation of hereditary factor VII deficiency. Semin Thromb Hemost 2000;26:393-400.
16. Wulff K, Herrmann FH. Twenty-two novel mutations of the factor VII gene in factor VII deficiency. Hum Mutat 2000;15:489-496.
17. Siegemund A, Petros S, Siegemund T, Scholz U, Seyfarth H-J, Engelmann L: The endogenous thrombin potential and high levels of coagulation factor VIII, factor IX and factor XI. Blood Coagul Fibrinolysis 2004;15:241-244.
18. Siegemund T, Petros S, Siegemund A, Scholz U, Engelmann L: Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb Haemost 2003;90:781-786.
19. Hemker HC, Béguin S: Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74:134-138.
20. Castoldi E, Govers-Riemslag JWP, Pinotti M, Biondini D, Tans G, Berrettini M, Mazzucconi MG, Bernardi F, Rosing J: Coinheritance of factor V (FV) Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726 + 5G>A (FVII Lazio) mutation. Blood 2003;102:4014-4020.
21. Zotz RB, Gerhardt A, Kluft C, Scharf RE: Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential. Thromb Haemost 2005;93:306-310.
22. Wielders S, Mukherjee M, Michiels J, Rijkers DTS, Cambus JP, Knebel RWC, Kakkar V, Hemker HC: The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost 1997;77:629-636.
23. Tans G, Rosendaal FR, Curvers J, Thomassen MCL, Bertina RM, Rosing J: APC resistance determined with the endogenous thrombin generation potential is associated with venous thrombosis: a blinded clinical evaluation (abstract 640). 17th Congr Int Soc Thromb Haemost, Washington, 1999. Thromb Haemost 1999;82(suppl):202.
24. Nichols WC, Amano K, Cacheris PM, Figueiredo MS, Michaelides K, Schwaab R, Hoyer L, Kaufman RJ, Ginsburg D: Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood 1996;88:1183-1187.
25. Vianello F, Belvini D, Dal Bello F, Tagariello G, Zanon E, Lombardi A-M, Zerbinati P, Girolami A: Mild bleeding diathesis in a boy with combined severe haemophilia B (C10400-→T) and heterozygous factor V Leiden. Haemophilia 2001;7:511-514.
26. van't Veer C, Golden NJ, Kalafatis M, Simioni P, Bertina RM, Mann KG: An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN). Blood 1997;90:3067-3072.
27. Arbini AA, Mannucci PM, Bauer KA: Low prevalence of the factor V Leiden Mutation among 'severe' haemophiliacs with a 'milder' bleeding diathesis. Thromb Haemost 1995;74: 1255-1258.
28. Arruda VR, Annichio-Bizzachi JM, Antunes SV, Costa FF: Association of severe haemophilia A and factor V Leiden: report of three cases. Haemophilia 1996;2:51-53.
29. Chan J, Weinmann AF, Thompson AR: Factor V Arg/Gln 506 has no dominant influence on the severity of haemophilia when inherited concurrently. Thromb Haemost 1995;73: 1368.